Neurocardiogenic syncope

	Neurocardiogenic Syncope Microchapters
Home
Patient Info
Overview
Pathophysiology
Epidemiology and Demographics
Risk Factors
Causes
Natural History, Complications & Prognosis
Differentiating Neurocardiogenic Syncope From Other Diseases
Diagnosis
History & Symptoms
Physical Examination
Tilt Table Testing
Treatment
Pharmacotherapy
Pacemaker therapy
Neurocardiogenic syncope On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neurocardiogenic syncope All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neurocardiogenic syncope
CDC on Neurocardiogenic syncope
Neurocardiogenic syncope in the news
Blogs on Neurocardiogenic syncope
Directions to Hospitals Treating Neurocardiogenic Syncope
Risk calculators and risk factors for Neurocardiogenic syncope

For patient information on this page, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Neurocardiogenic syncope. Carol Chen-Scarabelli, Tiziano M Scarabelli. BMJ 2004;329:336–41
Brignole M, Alboni P, Benditt D, Bergfeldt L, Blanc JJ, Bloch Thomsen PE, et al for the Task Force on Syncope, European Society of Cardiology.Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256-306.
Vasovagal Syncope. Alexis M. Fenton, MD; Stephen C. Hammill, MD; Robert F. Rea, MD; Phillip A. Low, MD; and Win-Kuang Shen, MD. Ann Intern Med. 2000;133:714-725.
Connolly SJ, Sheldon R, Thorpe KE, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289:2224-9.